Trovafloxacin: An Overview

• Published in: Pharmacotherapy 1999-01, Vol.19 (1), p.21-34
• Main Authors: Garey, Kevin W., Amsden, Guy W.
• Format: Article
• Language: English
• Subjects: Anti-Infective Agents - pharmacokinetics; Anti-Infective Agents - therapeutic use; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacterial Infections - drug therapy; Biological and medical sciences; Clinical Trials as Topic; Fluoroquinolones; Humans; Medical sciences; Multicenter Studies as Topic; Naphthyridines - pharmacokinetics; Naphthyridines - therapeutic use; Pharmacology. Drug treatments
• ISSN: 0277-0008; 1875-9114
• DOI: 10.1592/phco.19.1.21.30507

Trovafloxacin, a new synthetic naphthyridine fluoroquinolone antibiotic, is a broad‐spectrum agent available orally and intravenously. It was recently approved by the Food and Drug Administration for the treatment of selected pulmonary, surgical, intraabdominal, gynecologic, pelvic, skin, and urinary tract infections. Its spectrum of activity includes aerobic gram‐positive and gram‐negative organisms as well as anaerobic pathogens. It is rapidly absorbed after oral administration, achieves good tissue and cerebrospinal fluid penetration, and has a half‐life that allows once‐daily dosing. It is hepatically metabolized, and dosage adjustments are necessary for patients with severe hepatic dysfunction but not for those with mild or moderate dysfunction or renal dysfunction. The drug has a favorable safety profile, and a high tendency for transient first‐dose dizziness and/or lightheadedness in young women. Similar to other quinolones, trovafloxacin should not be taken with antacids that contain aluminum or magnesium, sucralfate, or ferrous sulfate. Trovafloxacin may prove beneficial as it allows for oral or intravenous monotherapy against indicated infections that normally require multidrug, broad‐spectrum antibiotic coverage.